ArticleScientific reports2026
Remnant cholesterol is independently associated with liver fibrosis in metabolic dysfunction-associated fatty liver disease patients and rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Few studies have explored the relationship between remnant cholesterol (RC) and liver fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD). Therefore, this study aims to explore the association between RC levels and liver fibrosis in both biopsy-proven MAFLD population and Sprague-Dawley (SD) rats. This current study included 280 participants and 15 SD rats. For MAFLD population, all participants underwent liver biopsy and blood tests. Logistic regression analysis was used to evaluate the association between RC and liver fibrosis and the diagnostic capability of RC was assessed using receiver operating characteristic (ROC) curve analysis. For MAFLD rats, pathological and hematological analysis were used to study the association between RC and liver fibrosis. In the MAFLD population, RC remained significantly associated with liver fibrosis after adjustment for confounding factors (OR:1.21, 95% confidence interval [CI]: 1.09-1.49, p < 0.001). In addition, RC and liver fibrosis remained significantly associated with liver fibrosis when triglycerides (TGs) levels were less than 1.7 mmol/L (OR: 1.13, 95% CI: 1.03-1.56, p = 0.006), low-density lipoprotein cholesterol (LDL-C) levels were less than 3.4 mmol/L (OR: 1.18, 95% CI: 1.08-1.43, p < 0.001), or HDL-C (high-density lipoprotein cholesterol) levels were more than 1.0 mmol/L (OR: 1.20, 95% CI: 1.08-1.47, p < 0.001). In the MAFLD rats, rats with fibrosis exhibited higher RC levels (p < 0.001) and elevated RC was significantly correlated with liver fibrosis (r = 0.819, p < 0.001). Higher RC level is significantly correlated with liver fibrosis in the MAFLD population and rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.